Oblita
  • About us
    • Who we are
    • Our motivation
    • How we work
    • Contact us
  • Team
    • Management team
    • Scientific Advisory Board
    • Board of Directors
  • Product
    • D121
  • Global Health
    • Commitment
    • Priority Review Voucher
    • Leishmaniasis
    • Chagas Disease
    • Fungal infections
    • Cryptosporidium infection
  • Investors
  • News
Select Page

Preclinical research demonstrates D121 outcompetes miltefosine

View full article (.pdf)

© Oblita Therapeutics – global health research & development

TT4CL

  • Follow
  • Follow